BidaskClub upgraded shares of USANA Health Sciences, Inc. (NYSE:USNA) from a strong sell rating to a sell rating in a report released on Tuesday.

Separately, Pivotal Research reduced their price objective on USANA Health Sciences from $75.00 to $70.00 and set a buy rating on the stock in a research note on Wednesday, July 26th.

Shares of USANA Health Sciences (NYSE USNA) traded up 1.44% during midday trading on Tuesday, reaching $59.85. The company’s stock had a trading volume of 23,994 shares. The stock’s 50-day moving average price is $59.64 and its 200-day moving average price is $60.22. The company has a market cap of $1.46 billion, a P/E ratio of 15.55 and a beta of 1.10. USANA Health Sciences has a 12-month low of $52.55 and a 12-month high of $75.00.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.08. The company had revenue of $257.10 million for the quarter, compared to analyst estimates of $273.61 million. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.07 EPS. On average, analysts expect that USANA Health Sciences will post $3.79 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/25/usana-health-sciences-inc-usna-lifted-to-sell-at-bidaskclub.html.

USANA Health Sciences announced that its Board of Directors has initiated a share buyback program on Tuesday, July 25th that allows the company to buyback $64.60 million in outstanding shares. This buyback authorization allows the company to purchase up to 46% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

In other news, Director Myron W. Wentz sold 40,000 shares of USANA Health Sciences stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $64.15, for a total transaction of $2,566,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul A. Jones sold 9,851 shares of USANA Health Sciences stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $64.50, for a total value of $635,389.50. Following the sale, the insider now directly owns 6,020 shares in the company, valued at $388,290. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 236,140 shares of company stock worth $14,198,464. Corporate insiders own 53.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Trexquant Investment LP raised its stake in shares of USANA Health Sciences by 363.6% in the first quarter. Trexquant Investment LP now owns 16,700 shares of the company’s stock worth $962,000 after buying an additional 13,098 shares during the last quarter. Nine Chapters Capital Management LLC acquired a new stake in shares of USANA Health Sciences during the first quarter worth about $207,000. Ameriprise Financial Inc. raised its stake in shares of USANA Health Sciences by 19.6% in the first quarter. Ameriprise Financial Inc. now owns 44,563 shares of the company’s stock worth $2,567,000 after buying an additional 7,305 shares during the last quarter. Karp Capital Management Corp acquired a new stake in shares of USANA Health Sciences during the first quarter worth about $595,000. Finally, Ramsey Quantitative Systems acquired a new stake in shares of USANA Health Sciences during the first quarter worth about $507,000. 43.57% of the stock is currently owned by institutional investors and hedge funds.

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Receive News & Stock Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related stocks with our FREE daily email newsletter.